Brookline, MA, United States of America

Thomas Boehm


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Thomas Boehm

Introduction

Thomas Boehm is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of medical research, particularly in the development of antiangiogenic therapies. His work focuses on innovative solutions to combat diseases related to angiogenesis.

Latest Patents

Thomas Boehm holds a patent for "Antibodies to antiangiogenic compositions and methods." This patent describes an antibody to the endostatin protein, which acts as an inhibitor of endothelial cell proliferation. The antibody is capable of inhibiting angiogenesis and promoting tumor regression. It is characterized by a molecular weight of approximately 18 kDa as determined by non-reduced gel electrophoresis and approximately 20 kDa as determined by reduced gel electrophoresis. This invention corresponds to a C-terminal fragment of collagen type XVIII and includes methods for detecting and treating angiogenesis-related diseases.

Career Highlights

Boehm is associated with the Children's Medical Center Corporation, where he continues to advance his research and innovations. His work has the potential to impact the treatment of various diseases significantly.

Collaborations

Thomas Boehm has collaborated with esteemed colleagues, including Michael S. O'Reilly and M. Judah Folkman. Their combined expertise has contributed to the advancement of medical research and the development of new therapeutic strategies.

Conclusion

Thomas Boehm's contributions to the field of antiangiogenic therapies highlight his innovative spirit and dedication to medical research. His patent on endostatin antibodies represents a significant step forward in the fight against angiogenesis-related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…